New Trends in the Design of Drugs Against Alzheimers Disease

P.      Francotte; E.      Graindorge; S.      Boverie; P.   de   Tullio; B.      Pirotte

doi:10.2174/0929867043364946

Abstract

First described by Alois Alzheimer in 1907, Alzheimers disease (AD) is the most common dementia type, affecting approximately 20 million people worldwide. As the population is getting older, AD is a growing health problem. AD is currently treated by symptomatic drugs, the acetylcholinesterase inhibitors, based on the cholinergic hypothesis (1976). During the past decade, advances in neurobiology have conducted to the identification of new targets. Although some of these innovative approaches tend to delay onset of AD, others are still symptomatic. In this review, we present an overview of the several strategies and new classes of compounds against AD.

Keywords: Alzheimer, neurobiology, acetylcholinesterase, cholinergic

« Previous Next »